C-KIT is a recognized proto-oncogene that has been identified in GIST, acute myelogenous leukemia (AML) and mastocytosis (58) and the KIT protein is the target of clinical tyrosine kinase inhibitors such as imatinib. This evidence concerns the gene KIT and gastrointestinal stromal tumor.